ViroPharma Reports Encouraging Data
ViroPharma Inc. (NASDAQ:VPHM) announced that positive data on Plenadren was recently published in the Journal of Clinical Endocrinology and Metabolism. The drug was approved by the European regulatory body in November last year for use as a treatment for adrenal insufficiency in adults. The study results demonstrated that patients dosed with Plenadren once daily experienced [...]
ViroPharma Inc. (NASDAQ:VPHM) announced that positive data on Plenadren was recently published in the Journal of Clinical Endocrinology and Metabolism. The drug was approved by the European regulatory body in November last year for use as a treatment for adrenal insufficiency in adults.
The study results demonstrated that patients dosed with Plenadren once daily experienced a better circadian-based serum cortisol profile, lower body weight, lower blood pressure, and improved glucose metabolism, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards